<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104672</url>
  </required_header>
  <id_info>
    <org_study_id>AB680CSP0002</org_study_id>
    <nct_id>NCT04104672</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability,&#xD;
      pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with&#xD;
      Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and&#xD;
      gemcitabine will be assessed in participants with advanced pancreatic cancer. In this dose&#xD;
      escalation combination study, participants with advanced pancreatic cancer will receive&#xD;
      escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose&#xD;
      (RP2D), and nab-paclitaxel and gemcitabine at standard doses. AB680, Zimberelimab,&#xD;
      nab-paclitaxel and gemcitabine are all administered via IV infusion.&#xD;
&#xD;
      In the dose expansion phase of the study, participants with advanced pancreatic cancer will&#xD;
      receive AB680 at the RP2D determined from the dose escalation study in combination with&#xD;
      Zimberelimab at the RP2D and nab-paclitaxel and gemcitabine at standard doses or AB680 at the&#xD;
      RP2D in combination with nab-paclitaxel and gemcitabine at standard doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 Dose escalation design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0</measure>
    <time_frame>From first dose date to 90 days after the last dose (approximately 1 year)</time_frame>
    <description>Number of participants treated with AB680 in combination with Zimberelimab and nab-paclitaxel and gemcitabine with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AB680 peak plasma concentration (Cmax)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 36, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Peak plasma concentration (Cmax) of AB680</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab peak plasma concentration (Cmax)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Peak plasma concentration (Cmax) of Zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AB680 time of peak concentration (Tmax)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 36, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Time of peak concentration (Tmax) of AB680</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab time of peak concentration (Tmax)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Time of peak concentration of Zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AB680 area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 36, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of AB680</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1 (sequential), day 2, day 3, day 8, day 15, day 29, day 43, day 57, day 85, day 197, day 309, day 421, 30 days after last dose, and 90 days after last dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of Zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indicators: anti-drug antibodies (ADA)</measure>
    <time_frame>Day 1, day 15, day 29, day 57, day 85, day 197, day 309, and day 421</time_frame>
    <description>Number of participants who develop anti-drug antibodies to Zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>First dose date to progression or last tumor assessment, up to 1 year</time_frame>
    <description>Number of Participants with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Start date of response to first progression/death, up to 1 year</time_frame>
    <description>Time at which response criteria are met for complete response or partial response (whichever occurs first) until the first date of recurrence, progression or death per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>First dose date to first progression/death, up to 1 year</time_frame>
    <description>Number of participants with complete response, partial response, or stable disease for greater than 6 months per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>First dose date to first progression/death, up to 1 year</time_frame>
    <description>Number of participants without disease progression per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>First dose date to date of death, up to 1 year</time_frame>
    <description>Overall survival rate, defined as time between first dose date and date of death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic effects of AB680</measure>
    <time_frame>Day 1, day 2, day 8, day 15, day 29, day 36, day 43, day 57, and day 85</time_frame>
    <description>Enzymatic activity of CD73 measured in participant blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>AB680 cytokines</measure>
    <time_frame>Day 1, day 2, day 8, day 15, day 29, day 36, day 43, day 57, and day 85</time_frame>
    <description>Cytokines may be summarized by dose group and subject over time by aggregating data from exploratory biomarkers collected from peripheral blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>AB680 immunophenotyping</measure>
    <time_frame>Day 1, day 2, day 8, day 15, day 29, day 36, day 43, day 57, and day 85</time_frame>
    <description>Immunophenotyping may be summarized by dose group and subject over time by aggregating data from exploratory biomarkers collected from peripheral blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>AB680 gene expression</measure>
    <time_frame>Day 1, day 2, day 8, day 15, day 29, day 36, day 43, day 57, and day 85</time_frame>
    <description>Gene expression may be summarized by dose group and subject over time by aggregating data from exploratory biomarkers collected from peripheral blood samples</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (AB680 + Zimberelimab + NP/Gem)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with Zimberelimab at the RP2D and the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (AB680 + NP/Gem)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB680</intervention_name>
    <description>AB680 is a Cluster of Differentiation (CD)73 Inhibitor.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + NP/Gem)</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + Zimberelimab + NP/Gem)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + Zimberelimab + NP/Gem)</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + NP/Gem)</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + Zimberelimab + NP/Gem)</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + NP/Gem)</arm_group_label>
    <arm_group_label>Dose Expansion (AB680 + Zimberelimab + NP/Gem)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving signed informed consent&#xD;
&#xD;
          2. Male or female participants ≥ 18 years of age at the time of screening&#xD;
&#xD;
          3. Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1;&#xD;
             negative serum or urine pregnancy test on the first day of each subsequent treatment&#xD;
             period&#xD;
&#xD;
          4. Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma&#xD;
&#xD;
          5. Naïve to any prior treatment, including chemotherapy, biological therapy, or targeted&#xD;
             therapy for metastatic disease&#xD;
&#xD;
               1. Prior adjuvant therapy (including chemotherapy and/or radiotherapy) for&#xD;
                  pancreatic adenocarcinoma is permitted if neoadjuvant or adjuvant therapy was&#xD;
                  completed at least 6 months prior to study enrollment. Prior adjuvant therapy may&#xD;
                  include Nab- paclitaxel or gemcitabine&#xD;
&#xD;
               2. Participants initially diagnosed with locally advanced pancreatic cancer who have&#xD;
                  undergone chemotherapy then resection and had no evidence of disease are eligible&#xD;
                  if relapse of metastatic disease has occurred and if the last dose of&#xD;
                  chemotherapy was received more than 6 months before study entry&#xD;
&#xD;
          6. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if&#xD;
             the participant received prior radiation&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1&#xD;
&#xD;
          8. Confirmation that an archival tissue sample is available; if not, a new biopsy of a&#xD;
             tumor must be obtained&#xD;
&#xD;
          9. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed&#xD;
             topical corticosteroids (doses &gt; 10 mg/day prednisone or equivalent) must be&#xD;
             discontinued at least 2 weeks (14 days) before investigational product administration.&#xD;
             Physiologic doses of corticosteroids (≤ 10 mg/day of prednisone or its equivalent) or&#xD;
             short pulses of corticosteroids (≤ 3 days) may be permitted&#xD;
&#xD;
         10. Prior surgery that required general anesthesia or other major surgery as defined by&#xD;
             the Investigator must be completed at least 4 weeks before investigational product&#xD;
             administration&#xD;
&#xD;
         11. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or&#xD;
             hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human&#xD;
             immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening&#xD;
&#xD;
         12. Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within&#xD;
             4 weeks (28 days) of initiation of investigational product&#xD;
&#xD;
          2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will&#xD;
             make the administration of investigational product hazardous (eg, interstitial lung&#xD;
             disease, active infections requiring antibiotics, recent hospitalization with&#xD;
             unresolved symptoms&#xD;
&#xD;
          3. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          4. Any active autoimmune disease or a documented history of autoimmune disease or history&#xD;
             of a syndrome that required systemic steroids or immunosuppressive medications, except&#xD;
             for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require&#xD;
             intermittent use of bronchodilators (such as albuterol) will not be excluded from this&#xD;
             study&#xD;
&#xD;
          5. Prior malignancy active within the previous year except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6200</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omid Hamid</last_name>
      <email>ohamid@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Vi K Chiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <email>LYonemoto@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev Weinburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Lacy</last_name>
      <email>jill.lacy@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Lacy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan MacDougall</last_name>
      <phone>314-273-2637</phone>
      <email>macdougallm@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Kian-Huat Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Weren</last_name>
      <email>Kelsey.Weren@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Paul Oberstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Manrique</last_name>
      <phone>212-342-4276</phone>
      <email>dm3489@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gulam Manji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Ragazzo</last_name>
      <phone>646-888-4182</phone>
      <email>ragazzos@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eileen O'Reilly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Martin</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48455</phone_ext>
      <email>Stacie-Martin@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Susanna Ulahannan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark O'Hara</last_name>
      <email>Mark.O'hara@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Mark O'Hara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica DePue</last_name>
      <phone>215-955-1588</phone>
      <email>Jessica.DePue@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>James Posey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rhee</last_name>
    </contact>
    <investigator>
      <last_name>Nathan Bahary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Canon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Spigel</last_name>
    </contact>
    <investigator>
      <last_name>Johanna Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saman Chishty</last_name>
      <phone>713-563-0060</phone>
      <email>SChishty@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Uboha</last_name>
      <email>nvuboha@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Nataliya Uboha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

